DOI QR코드

DOI QR Code

Increasing of Macrophage Migration Inhibitory Factor Expression in Human Patients Infected with Virulent Brucella in Iraq

  • Khudhur, Hasan R. (Department of Medical Microbiology, AL-Muthanna University) ;
  • Menshed, Abbas Ali (Ministry of Education, Al-Furat Al-Awsat Technical University) ;
  • Hasan, Ahmed Abbas (College of Health and Medical Techniques, Al-Furat Al-Awsat Technical University)
  • Received : 2020.07.26
  • Accepted : 2020.08.28
  • Published : 2020.12.28

Abstract

Brucellosis is a zoonotic disease caused by Brucella infections and humans usually contract this disease from close contact with infected animals or their products, usually via the ingestion of cheese or crude milk. Macrophage migration inhibitory factor (MIF) and Pro- and anti-inflammatory cytokines play an important role in susceptibility/resistance and the immunopathogenesis of Brucella infection. These cytokines are crucial factors in the initiation and progression of protective immunity against Brucella infection but the role of MIF has not been well studied in the human response to intracellular microbes. This study was designed to investigate the effect of MIF expression on Brucella susceptibility. A total of 85 positive rose Bengal tests and 24 samples from healthy individuals were collected for this study and subjected to polymerase chain reaction assays (PCR) of the bcsp31 diagnostic gene. MIF concentrations were evaluated using Enzyme-Linked immunosorbent assay (ELISA) and the results showed that 46 (54%) of the rose Bengal test samples were positive and 39 (46%) were negative for bcsp31 (p ≤ 0.05) and used as the gold standard for all of the comparisons in this study. The ELISA results indicate that the mean concentration of MIF was significantly higher in patients with positive rose Bengal tests when compared to the control groups and that its concentration increases with increasing age in both the patient and control groups (p ≤ 0.05).

Keywords

References

  1. Franco MP, Mulder M, Gilman RH, Smits HL. 2007. Human brucellosis. Lancet Infect. Dis. 7: 775-786. https://doi.org/10.1016/S1473-3099(07)70286-4
  2. Jihan S, Khorsheed HO, Salih SM. 2007. Incidence of brucellosis in Kirkuk Province using simple dilution microagglutination rose Bengal test method. Med. J. Tikrit. 1: 70-74.
  3. Tsolis RM. 2002. Comparative genome analysis of the α-proteobacteria: relationships between plant and animal pathogens and host specificity. Proc. Natl. Acad. Sci. USA 99: 12503-12505. https://doi.org/10.1073/pnas.212508599
  4. Xavier M, Paixão T, Poester F, Lage A, Santos R. 2009. Pathological, immunohistochemical and bacteriological study of tissues and milk of cows and fetuses experimentally infected with Brucella abortus. J. Comp. Pathol. 140: 149-157. https://doi.org/10.1016/j.jcpa.2008.10.004
  5. Poester F, Samartino L, Santos R. 2013. Pathogenesis and pathobiology of brucellosis in livestock. Rev. Sci. Tech. 32: 105-115. https://doi.org/10.20506/rst.32.1.2193
  6. Neta AVC, Stynen AP, Paixao TA, Miranda KL, Silva FL, Roux CM, et al. 2008. Modulation of the bovine trophoblastic innate immune response by Brucella abortus. Infect. Immun. 76: 1897-1907. https://doi.org/10.1128/IAI.01554-07
  7. Ali AF, Radwan ME, Abdelwahab MG, Hamoda AF. 2017. Investigation on cytotoxic effect of Brucella Abortus infection on cattle and the role of cytokines in regulation of intracellular bacterial infection. Arch. Epidemiol. DOI:10.29011/AEPD-101.000001.
  8. Zhang L, Wu XA, Zhang FL, An CH, Sun YX, Bai WT, et al. 2012. Soluble expression and purification of Brucella cell surface protein (BCSP31) of Brucella melitensis and preparation of anti-BCSP31 monoclonal antibodies. Mol. Biol. Rep. 39: 431-438. https://doi.org/10.1007/s11033-011-0755-9
  9. Al Dahouk S, Nockler K, Scholz HC, Pfeffer M, Neubauer H, Tomaso H. 2007. Evaluation of genus-specific and species-specific real-time PCR assays for the identification of Brucella spp. Clin. Chem. Lab. Med. 45: 1464-1470. https://doi.org/10.1515/CCLM.2007.305
  10. Skendros P, Boura P. 2013. Immunity to brucellosis. Rev. Sci. Tech. 32: 137-147. https://doi.org/10.20506/rst.32.1.2190
  11. Hou G, Valujskikh A, Bayer J, Stavitsky AB, Metz C, Heeger PS. 2001. In vivo blockade of macrophage migration inhibitory factor prevents skin graft destruction after indirect allorecognition. Transplantation 72: 1890-1897. https://doi.org/10.1097/00007890-200112270-00005
  12. Ferro EAV, Mineo JR, Ietta F, Bechi N, Romagnoli R, Silva DAO, et al. 2008. Macrophage migration inhibitory factor is up-regulated in human first-trimester placenta stimulated by soluble antigen of Toxoplasma gondii, resulting in increased monocyte adhesion on villous explants. Am. J. Pathol. 172: 50-58. https://doi.org/10.2353/ajpath.2008.070432
  13. Alomashi G, Khudhur H. 2018. MIF G-173C polymorphism and susceptibility to cutaneous leishmaniasis in Iraq. J. Nanomed. Res. 7: 89-91.
  14. Kobayashi K, Allred C, Castriotta R, Yoshida T. 1985. Strain variation of bacillus Calmette-Guerin-induced pulmonary granuloma formation is correlated with anergy and the local production of migration inhibition factor and interleukin 1. Am. J. Pathol. 119: 223-235.
  15. Yamada G, Shijubo N, Takagi-Takahashi Y, Nishihira J, Mizue Y, Kikuchi K, et al. 2002. Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin. Immunol. 104: 123-127. https://doi.org/10.1006/clim.2002.5255
  16. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, et al. 2002. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin. Diagn. Immunol. 9: 251-256.
  17. Wang Y, Wang Z, Zhang Y, Bai L, Zhao Y, Liu C, et al. 2014. Polymerase chain reaction-based assays for the diagnosis of human brucellosis. Ann. Clin. Microbiol. Antimicrob. 13: 31. https://doi.org/10.1186/s12941-014-0031-7
  18. Team RC. 2015. R Foundation for Statistical Computing; Vienna, Austria: 2014. R: A language and environment for statistical computing.
  19. Yagupsky P. 2014. Brucellae growing on Thayer-Martin medium: a source of inadvertent exposure for laboratory personnel in endemic areas. J. Med. Microbiol. 63: 148-149. https://doi.org/10.1099/jmm.0.064121-0
  20. Khosravi AD, Abassi E, Alavi SM. 2006. Isolation of Brucella melitensis and Brucella abortus from brucellosis patients by conventional culture method and polymerase chain reaction technique. Pak. J. Med. Sci. 22: 396-400.
  21. Cekovska Z, Petrovska M, Jankoska G, Panovski N, Kaftandzieva A. 2010. Isolation, identification and antimicrobial susceptibility of brucella blood culture isolates. Prilozi 31: 117-132.
  22. Karem A Sh, Al-Jindeel TJ. 2016. Immunological study and molecular detection on human brucellosis patients in al-muthanna government. Life Sci. Arch. 2: 765-762.
  23. Briones-Lara E, del C Palacios-Saucedo G, Martinez-Vazquez IO, Morales-Loredo A, del Pilar Bilbao-Chavez L. 2007. Response to the treatment of brucellosis among children. Evaluation with Huddleson reaction and PCR. Rev. Méd. Inst. Mex. Seguro Soc. 45: 615-622.
  24. Renner P, Roger T, Calandra T. 2005. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clinical infectious diseases. 41(Supplement_7): S513-S519. https://doi.org/10.1086/432009
  25. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, et al. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. 99: 345-350. https://doi.org/10.1073/pnas.012511599
  26. Courville P, Chaloupka R, Cellier M. 2006. Recent progress in structure-function analyses of Nramp proton-dependent metalion transporters. Biochem. Cell Biol. 84: 960-978. https://doi.org/10.1139/o06-193
  27. Oddo M, Calandra T, Bucala R, Meylan PR. 2005. Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages. Infect. Immun. 73: 3783-3786. https://doi.org/10.1128/IAI.73.6.3783-3786.2005
  28. Khudhur HR, Alomashi GB. 2018. Effect of NRAMP1 gene polymorphism on levels of (TNF-α1 and IL-1β) cytokines in cutaneous Leishmaniasis patients in Iraq. J. Immunol. Clin. Microbiol. 3: 15-22.
  29. Covas CdJF, Cardoso CC, Gomes-Silva A, Oliveira JRS, Da-Cruz AM, Moraes MO. 2013. Candidate gene case-control and functional study shows macrophage inhibitory factor (MIF) polymorphism is associated with cutaneous leishmaniasis. Cytokine 61: 168-172. https://doi.org/10.1016/j.cyto.2012.09.012